chiauranib + etoposide

**chiauranib + etoposide** is a combination therapy comprising **chiauranib**, a novel small-molecule multi-targeted kinase inhibitor, and **etoposide**, a cytotoxic chemotherapy agent. Chiauranib selectively inhibits multiple kinase pathways, including *Vascular Endothelial Growth Factor Receptor* (VEGFR), *Aurora kinase B*, and *Colony Stimulating Factor 1 Receptor* (CSF-1R), thereby blocking tumor angiogenesis, regulating immune microenvironment, and interrupting cell cycle progression. Etoposide inhibits *topoisomerase II*, causing DNA breaks and apoptosis in rapidly dividing cells. The combination has shown enhanced antitumor efficacy and manageable safety in clinical trials for platinum-resistant or refractory ovarian cancer, with a focus on patients who have undergone multiple prior treatments. Primary clinical endpoints include progression-free survival and overall response rate.[1][2]